Thrombo-inflammation Biomarkers Trial in Acute Cerebral Hypoxia. a Case-control Trial Nested in a Cohort

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

The goal of this trial is to study, in three well-defined clinical situations responsible for cerebral hypoxia, the concentrations of biomarkers of thrombo-inflammation compared to a population of patients without cerebral hypoxia, and to study in patients with cerebral hypoxia the association between these concentrations and the clinical evolution.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

⁃ \- For cases, admitted within the first 36 hours of an acute neurological symptom related to :

• An ischaemic cerebrovascular accident (iCVA) eligible for a mechanical thrombectomy procedure,

• A subarachnoid haemorrhage (SAH, all aetiologies) : patient presenting with at least a modified Fisher scale 3 or 4,

• An intra-parenchymal haematoma (IPH) with greatest axis ≥ 20mm or with NIHSS on admission \>4.

⁃ OR

• For control patients, admitted within 7 days of the onset of acute neurological symptomatology related to a clinical diagnosis of transient ischaemic attack (TIA) - based on thorough questioning of the patient on admission - and prior to imaging, with an ABCD2≥ 2 score.

• Express consent to participate in the study.

• Member or beneficiary of a social security.

Locations
Other Locations
France
Hôpital Fondation Adolphe de Rothschild
RECRUITING
Paris
Contact Information
Primary
François DELVOYE
fdelvoye@for.paris
0148036556
Backup
Amélie Yavchitz
fyavchitz@for.paris
0148036556
Time Frame
Start Date: 2024-03-19
Estimated Completion Date: 2026-06-22
Participants
Target number of participants: 200
Treatments
Case
Patients with cerebral hypoxia victims of ischaemic stroke, acute parenchymal haemorrhage or subarachnoid haemorrhage
Control
Patients without cerebral hypoxia
Related Therapeutic Areas
Sponsors
Leads: Fondation Ophtalmologique Adolphe de Rothschild

This content was sourced from clinicaltrials.gov